COSTEM 2019 | Can third party CMV-specific T-cells replace drug therapy?

Catherine Bollard

Catherine Bollard, MD, MBChB, Children’s National Medical Center, Washington, DC, discusses the possibility of third party CMV-specific T-cells replacing drug therapy. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video